Epilepsy

As neurologists and other specialists may increasingly be called upon to serve as general hospitalists in the wake of the COVID-19 pandemic, keeping health care workers healthy becomes paramount.

The Tuberous Sclerosis Alliance (TS Alliance) have prepared an FAQ to address concerns from the tuberous sclerosis complex (TSC) community regarding the COVID-19 outbreak.

Neurology News Network for the week ending March 14, 2020.

The Engage Therapeutics product met its primary end point in the StATES study, with an onset of action for ceasing seizure activity of approximately 30 seconds, on average.

SK Life Science’s newly approved treatment for partial-onset seizures is set to launch in the second quarter of 2020, after being designated Schedule V by the DEA.

Despite the introduction of second-generation ASMs, drug tolerability has been relatively unchanged over the last 30 years.

Both the 10- and 20-mg doses were associated with clinically relevant reductions in convulsive seizures with a favorable safety and tolerability profile.

The drug was previously approved for the treatment of acute repetitive seizures and granted 7 years of orphan drug exclusivity in January 2020.

The new PDUFA action date has been set as June 25, 2020, a 3-month extension. The FDA informed Zogenix that additional data submission has constituted a major amendment to the NDA.

Imad Najm, MD, director of the Cleveland Clinic Epilepsy Center, detailed the ongoing efforts to transform the way health care providers diagnose and treat patients with 1 ultimate goal in mind: improving access to high-quality care.

Phenytoin is indicated for the treatment of tonic-clonic and psychomotor seizures in pediatric and adult patients.

Patients 65 and under were more likely to develop seizures following a stroke than older patients.

The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine discussed the reasons an adult with epilepsy may seek genetic testing and what benefits it can provide.

The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine spoke about the evolving landscape of the use of genetic tools in epilepsy.

Neurology News Network for the week ending February 15, 2020.

The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine discussed the use of genetic testing in the adult epilepsy population.

The professor of neurology and epilepsy specialist at the Cleveland Clinic Lerner College of Medicine discussed the difficult treatment decisions faced when undergoing epilepsy surgery.

Presurgical counseling can be improved by better understanding seizure outcomes associated with different surgery locations, pathologies, nonlesional epilepsy, and incomplete resections.

The Aquestive Therapeutics diazepam formulation is seeking to be second to market in the treatment of seizure clusters, with a targeted prescription drug user fee action date of September 27, 2020.

The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine discussed the use of genetic testing in the adult epilepsy population.

William O. Tatum, DO, discussed the additive value of smartphone video technology in diagnosing epilepsy.

Neurology News Network for the week ending February 8, 2020.

The investigational therapy met its primary end point, showing superiority to placebo in reducing the frequency of drop seizures in patients with Lennox-Gastaut syndrome.

This additional application, supported by data from the GWPCARE6 trial, seeks to expand the indication of cannabidiol to include seizures associated with tuberous sclerosis complex.

The director of the Pediatric Epilepsy Program and an MD candidate at Weill Cornell Medicine detail the steps needed to take to improve outcomes in status epilepticus.